Neural Therapeutics CEO Ian Campbell joined Steve Darling from Proactive to share the news that after 11 months of rigorous review, the company has received permission from Peru's Ministry of Agriculture to access genetic resources and their derivatives for the evaluation of the mescaline-containing cactus species of the Echinopsis genus, commonly known as San Pedro or Huachuma, for possible medicinal purposes.
The company's plan is to develop intellectual property that will pave the way for drug development using mescaline. Mescaline is a chemical compound classified as a psychedelic and has shown potential medicinal and therapeutic applications. It is derived from the Peyote and San Pedro cacti.
Neural Therapeutics is committed to sustainable practices throughout its exploration and development of mescaline-containing cacti. This includes replanting, donating samples for genetic preservation, and publishing biomarker data to aid in the preservation of wild stands of these cacti species.
The access to genetic resources and derivatives of the San Pedro cactus will enable Neural Therapeutics to further explore the potential medicinal benefits of mescaline. The company's efforts could lead to the development of novel therapeutic options and potentially expand treatment options for various medical conditions.
As the research progresses, Neural Therapeutics aims to ensure responsible and sustainable practices to safeguard the preservation of these valuable plant species. This approach aligns with the growing interest in harnessing the potential of natural compounds for therapeutic purposes while respecting the environment and preserving biodiversity.